|Articles|December 1, 2008

Gurvinder Singh Rekhi, PhD

Gurvinder Singh Rekhi, PhD

Gurvinder Singh Rekhi, PhD
Director, R&D,
Elan Drug Delivery, Inc.

Gurvinder Singh Rekhi, PhD, is currently director of research and development at Élan Drug Inc. in Gainesville, Georgia, managing the activities of the formulation and analytical development, scale-up/transfer, and validation of controlled release dosage forms. He is responsible for regulatory submissions for three NDAs, and he represents the company in contract negotiations, scientific/technical presentations, and intellectual property.

Rekhi is currently an adjunct assistant professor of pharmaceutics at the University of Maryland, School of Pharmacy, as well as an associate professor at the Massachusetts College of Pharmacy. Rekhi also serves as an advisory board member for the Center for Drug Delivery Research at Mercer University, Southern School of Pharmacy.

Rekhi is a member of professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), APhA, CRS, and Rho Chi Pharmaceutical Honor Society. He serves as an editorial board member of Pharmaceutical Technology and ad hoc reviewer for several pharmaceutical journals. He has served as a committee member on one MS, five PhD dissertations and directed two post-doctoral fellows. He has published and presented scientific papers in the US and at international conferences, and he holds numerous patents from the US Patent Office and several EU countries. He has co-authored chapters in the NABPLEX Pharmacy Review Book and the Handbook of Pharmaceutical Granulation Technology.

Rekhi received his B. Pharm. (1983) from Bombay College of Pharmacy, India. He obtained his MS (1986), BS (1989), and PhD (1991) degrees in Pharmaceutics and Industrial Pharmacy from Massachusetts College of Pharmacy. Rekhi is a registered pharmacist in the states of Connecticut, Maryland, and Georgia.

Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.